Incorporated in 1983, Dishman Carbogen Amcis Limited (DCAL) started out as a manufacturer of quaternary ammonium and phosphate compounds. Having ventured into the CRAMS space in India, the company soon became one of the fastest growing companies. Today, the company is a leading global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up, and manufacturing services.

The company aids drug innovators for development and process optimization for novel drug molecules in various stages of the development process. Once the innovative molecules are approved, the company further explore the possibility of large scale commercial supply tie-ups. The company is generating a healthy pipeline of contract manufacturing opportunities commensurate to the growing revenue base of manufacturing. Its robust business model is capable of sustaining growth, with CRAMS being the focal point of all its strategic efforts.

Business area of the company

The company is a fully integrated CRAMS player working with global pharmaceutical innovators. It has a global presence with development and manufacturing facilities across Europe, India, and China. It provides end-to-end, integrated, high-value, niche CRAMS offering, right from process research & development to late-stage clinical and commercial manufacturing facilities along with the supply of Active Pharmaceutical Ingredients (API) to innovator pharmaceutical companies.

Dishman Carbogen Amcis Ltd.

RPG Life Sciences Ltd.

Hester Biosciences Ltd.

Morepen Laboratories Ltd.

Solara Active Pharma Sciences Ltd.

Orchid Pharma Ltd.

TTK Healthcare Ltd.

Suven Life Sciences Ltd.

Bajaj Healthcare Ltd.

Alembic Ltd.

Supriya Lifescience Ltd.

Medicamen Biotech Ltd.

NGLFINE

IOL Chemicals And Pharmaceuticals Ltd.

Amrutanjan Health Care Ltd.

HDFC Bank Ltd.

ICICI Bank Ltd.

ITC Ltd.

Reliance Industries Ltd.

Tata Motors Ltd.

Market Cap	1,529 Cr		EPS	-3.6		High	98.5
Stock P/E	0.0		Net Profit Margin	-1.6		Low	97.15